Allarity (ALLR) Therapeutics announced that the European Patent Office, EPO, has issued a formal notice of its intention to grant a patent for Allarity’s Drug Response Predictor, DRP, companion diagnostic specific to stenoparib, the Company’s dual-targeted PARP/Tankyrase inhibitor. This patent represents a significant step forward in securing Allarity’s market position for stenoparib and the Stenoparib DRP companion diagnostic, which identifies patients most likely to derive clinical benefit from stenoparib treatment.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALLR:
- Allarity regains compliance with NASDAQ minimum bid price requirement
- ALLR Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Allarity names Jeremy Graff as president, CDO, Jose Iglesias as consultant CMO
- Allarity Therapeutics Strengthens Leadership for Cancer Programs
- Allarity Therapeutics Nears Regulatory Approval with Stenoparib Trial Success